Decernotinib

• Description:

  Decernotinib is a potent, orally active JAK3 inhibitor, with Kis of 2.5, 11, 13 and 11 nM for JAK3, JAK1, JAK2, and TYK2, respectively.

• Product Name Alternative:

  VX-509; VRT-831509

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  JAK

• Type:

  Reference compound

• Related Pathways:

  Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/Decernotinib.html

• Purity:

  99.91

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  C[C@](C(NCC(F)(F)F)=O)(CC)NC1=NC(C2=CNC3=NC=CC=C32)=NC=C1

• Molecular Formula:

  C18H19F3N6O

• Molecular Weight:

  392.38

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Mahajan S, et al. VX-509 is a potent and selective Janus kinase 3 (JAK3) inhibitor that attenuates inflammation in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015 Mar 11. pii: jpet.114.221176.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light, stored under nitrogen)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Phase 3

• Isoform:

  JAK1; JAK2; JAK3; Tyk2

• CAS Number:

  [944842-54-0]